Octapharma to Invest US$1.5 Billion in Rock Hill, South Carolina, USA
Introduction:
Octapharma has announced plans to invest US$1.5 billion to establish its first US-based manufacturing and production facility at Palmetto Research Park in Rock Hill, South Carolina.
Features:
The project involves the construction of a manufacturing and production unit at Palmetto Research Park in Rock Hill, South Carolina. The unit will be used to produce plasma-derived therapies for critical care applications, including treatments for immune disorders.
The unit will also manufacture products used in bleeding management and trauma care. Plasma collected through the company’s US plasma donation network will be processed into therapeutic medicines for the US market.
The development follows planning and zoning procedures involving authorities in Rock Hill and York County.
The development will also include an administrative campus for plasma donation operations.
Specific details on production capacity, site area, building size, processing equipment, cleanroom classifications, utility systems, automation platforms and quality-control systems have not been disclosed.
Construction is expected to begin in late 2026, with operations expected to commence in the mid-2030s.
Name: Octapharma
Type: New Construction
Budget: US$1.5 billion
Year: 2030
Specifications:
| Name: | Octapharma |
| Type: | New Construction |
| Budget: | US$1.5 billion |
| Year: | 2030 |
